Our Mission

Our mission is to generate therapeutic antibodies to novel cancer targets and develop new cancer drugs to provide meaningful treatments and cures for patients with aggressive and metastatic cancers.

Boston-based Biotech

We are developing a new Antibody and Antibody-Drug-Conjugate (ADC) therapeutics to treat and cure patients suffering from solid tumor and metastatic disease. Learn More

Strategy

Our drug development strategy is based on our belief that the solution to making better cancer drugs is to find better cancer targets. Learn More

Cancer Target and Antibody

We have developed a proprietary antibody platform and have generated a robust pipeline of antibodies to novel cancer targets. Our lead cancer drug, CM-09 is a First-in-Class ADC to treat patients with pancreatic and gastric cancers.
Learn More

Next Steps

We are transitioning from a preclinical to a clinical biotech and preparations are underway to take CM-09 into a human clinical cancer trial.